HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans
- PMID: 21428769
- PMCID: PMC3113609
- DOI: 10.1056/NEJMoa1013297
HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans
Abstract
Background: Carbamazepine causes various forms of hypersensitivity reactions, ranging from maculopapular exanthema to severe blistering reactions. The HLA-B*1502 allele has been shown to be strongly correlated with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) in the Han Chinese and other Asian populations but not in European populations.
Methods: We performed a genomewide association study of samples obtained from 22 subjects with carbamazepine-induced hypersensitivity syndrome, 43 subjects with carbamazepine-induced maculopapular exanthema, and 3987 control subjects, all of European descent. We tested for an association between disease and HLA alleles through proxy single-nucleotide polymorphisms and imputation, confirming associations by high-resolution sequence-based HLA typing. We replicated the associations in samples from 145 subjects with carbamazepine-induced hypersensitivity reactions.
Results: The HLA-A*3101 allele, which has a prevalence of 2 to 5% in Northern European populations, was significantly associated with the hypersensitivity syndrome (P=3.5×10(-8)). An independent genomewide association study of samples from subjects with maculopapular exanthema also showed an association with the HLA-A*3101 allele (P=1.1×10(-6)). Follow-up genotyping confirmed the variant as a risk factor for the hypersensitivity syndrome (odds ratio, 12.41; 95% confidence interval [CI], 1.27 to 121.03), maculopapular exanthema (odds ratio, 8.33; 95% CI, 3.59 to 19.36), and SJS-TEN (odds ratio, 25.93; 95% CI, 4.93 to 116.18).
Conclusions: The presence of the HLA-A*3101 allele was associated with carbamazepine-induced hypersensitivity reactions among subjects of Northern European ancestry. The presence of the allele increased the risk from 5.0% to 26.0%, whereas its absence reduced the risk from 5.0% to 3.8%. (Funded by the U.K. Department of Health and others.).
Figures


Comment in
-
Two papers on carbamazepine-induced hypersensitivity and its relationship to HLA status.J R Coll Physicians Edinb. 2011 Sep;41(3):221-2. doi: 10.4997/JRCPE.2011.308. J R Coll Physicians Edinb. 2011. PMID: 21949918 No abstract available.
-
Pharmacogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: a critical appraisal.Br J Dermatol. 2012 Jan;166(1):7-11; discussion 11-4. doi: 10.1111/j.1365-2133.2011.10754.x. Br J Dermatol. 2012. PMID: 22212057 No abstract available.
References
-
- Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209:123–9. - PubMed
-
- Syn WK, Naisbitt DJ, Holt AP, Pirmohamed M, Mutimer DJ. Carbamazepine-induced acute liver failure as part of the DRESS syndrome. Int J Clin Pract. 2005;59:988–91. [Erratum, Int J Clin Pract 2005;59: 1371.] - PubMed
-
- Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B★5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41:816–9. - PubMed
-
- Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428:486. - PubMed
-
- Chen P, Lin J-J, Lu C-S, et al. Carbamazepine-induced toxic effects and HLA-B★1502 screening in Taiwan. N Engl J Med. 2011;364:1126–33. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials